MAS1L Antibody

What is MAS1L and how does it differ from MAS1?

MAS1L (MAS1-like), also known as MAS-L or MRG (Mas-related G-protein coupled receptor MRG), is a 378 amino acid multi-pass membrane protein belonging to the G-protein coupled receptor 1 (GPCR) family . While MAS1L shares structural similarities with MAS1, they have distinct functions. MAS1L is primarily associated with nociceptor function and development, including the sensation or modulation of pain . In contrast, MAS1 functions as a receptor for angiotensin 1-7 and acts as a functional antagonist of AGTR1 (angiotensin-2 type 1 receptor) . MAS1 regulates AGTR1 receptor levels through activation of G-proteins GNA11 and GNAQ, and stimulation of the protein kinase C signaling cascade .

What critical considerations should researchers make when selecting an anti-MAS1L antibody?

When selecting an anti-MAS1L antibody, researchers should carefully consider:

• The immunogen used to generate the antibody, as antibodies raised against different MAS1L domains yield different patterns of reactivity . For example, some commercial antibodies target synthetic peptides within the N-terminal region (aa 1-100) , while others may target different epitopes.

• The validated applications for which the antibody has been thoroughly tested. Different antibodies are optimized for specific techniques such as Western Blotting (WB), Immunocytochemistry/Immunofluorescence (ICC/IF), or Flow Cytometry .

• Species reactivity and cross-reactivity profiles. Some antibodies are validated for multiple species including human, mouse, and rat , while others may have more limited reactivity profiles .

• Published validation studies, particularly those that employ knockout models. A critical validation study revealed that many commercial MasR antibodies produced identical staining patterns in samples from both wild-type and MasR knockout mice, indicating potential specificity issues .

How should researchers approach MAS1L antibody validation in their experimental system?

Proper validation requires a multi-step approach:

What are the optimal Western blotting protocols for detecting MAS1L?

For effective Western blotting detection of MAS1L:

• Sample preparation: Use whole cell lysates from appropriate cell lines (MCF7, HeLa, A549, HepG2, PC-3, Jurkat have been validated for human samples; rat liver tissue lysate for rat samples) .

• Antibody dilution: Optimal dilution for monoclonal antibodies is typically 1/1000 for Western blotting , though this may vary with different antibodies and should be empirically determined.

• Secondary antibody selection: Use an appropriate species-specific secondary antibody, such as Goat polyclonal to rabbit IgG at 1/50000 dilution when working with rabbit primary antibodies .

• Expected results: Look for bands at the predicted size of 36-50 kDa or 42 kDa , depending on the specific antibody and any post-translational modifications in your experimental system.

• Controls: Include positive controls from cell lines with known MAS1L expression and, if possible, negative controls from MAS1L-knockout sources to confirm specificity .

What are the recommended protocols for immunofluorescence detection of MAS1L?

For immunofluorescence applications:

• Cell fixation: Fix cells in 4% formaldehyde and block in 10% normal Goat Serum to reduce non-specific binding .

• Primary antibody incubation: For monoclonal antibodies like ab314026, use a 1:50 dilution and incubate overnight at 4°C . For polyclonal antibodies like ab235914 (targeting MAS1), a 1:100 dilution has been validated .

• Secondary antibody selection: Use fluorescently-labeled secondary antibodies such as Alexa Fluor® 595-conjugated Goat Anti-Rabbit IgG(H+L) or Alexa Fluor 488® conjugated Goat Anti-Rabbit IgG .

• Counterstaining: Use DAPI for nuclear visualization to help localize cellular expression patterns .

• Validation: Compare staining patterns with those previously reported and, ideally, include appropriate knockout controls. Be aware that several commercial antibodies have shown identical staining patterns in both wild-type and knockout tissues, indicating potential non-specificity .

How can researchers differentiate between specific and non-specific binding when using MAS1L antibodies?

To distinguish specific from non-specific binding:

• Include peptide competition assays where the antibody is pre-incubated with the immunizing peptide prior to application. Specific binding should be blocked by this treatment .

• Employ tissues or cells from MAS1L knockout models as negative controls. The absence of signal in knockout samples would confirm specificity .

• Use multiple antibodies targeting different epitopes of MAS1L and compare their staining patterns. Consistent patterns across different antibodies suggest specific detection .

• Compare results across multiple techniques (WB, ICC/IF, Flow Cytometry) to build confidence in specificity .

• Be particularly cautious with GPCR antibodies, as studies have demonstrated that lack of specificity is frequent for antibodies directed against various GPCRs, including adrenoceptors, muscarinic, dopamine, and angiotensin receptors .

How should researchers interpret conflicting results when using different commercial MAS1L antibodies?

When faced with conflicting results:

• Consider the antibody's target epitope. Antibodies raised against different domains of MAS1L have been shown to yield different patterns of reactivity . Map the epitope locations and evaluate whether differences might be explained by detection of different protein conformations or isoforms.

• Evaluate antibody validation evidence. Prioritize antibodies with thorough validation, especially those tested against knockout controls .

• Perform additional validation experiments using genetic approaches like siRNA knockdown or CRISPR-Cas9 gene editing to confirm specificity in your experimental system.

• Consider that post-translational modifications might affect epitope accessibility or antibody recognition in different experimental contexts or tissue types.

• Consult the literature on similar GPCRs, as specificity issues have been widely reported for antibodies targeting various receptor types including adrenoceptors, muscarinic, dopamine, and angiotensin receptors .

What approaches can researchers use to study MAS1L expression in tissues with low abundance?

For detecting low-abundance MAS1L:

• Signal amplification techniques: Consider using tyramide signal amplification (TSA) or other amplification methods to enhance detection sensitivity while maintaining specificity.

• Enrichment strategies: Use cellular fractionation to concentrate membrane proteins before analysis, as MAS1L is a multi-pass membrane protein .

• Alternative detection methods: Consider complementing antibody-based methods with mRNA detection techniques like RT-qPCR or RNA-seq to confirm expression at the transcript level.

• Optimized antibody selection: Choose high-affinity antibodies with demonstrated sensitivity. Monoclonal antibodies may offer greater consistency in detecting low-abundance targets .

• Extended exposure times: For Western blots, longer exposure times may be needed, though care must be taken to evaluate non-specific background signal.

How can researchers effectively differentiate between MAS1L and closely related G-protein coupled receptors?

To differentiate between MAS1L and related GPCRs:

• Select antibodies raised against unique epitopes with minimal sequence homology to other GPCRs. Antibodies targeting the N-terminal region (aa 1-100) of MAS1L have been used successfully .

• Perform parallel experiments with antibodies specific to other GPCRs of interest to compare expression patterns.

• Use molecular techniques like RT-PCR with primers specific to unique regions of MAS1L to confirm antibody findings.

• Consider using heterologous expression systems to validate antibody specificity by comparing detection in cells overexpressing MAS1L versus those expressing related receptors .

• Be aware of the known cross-reactivity patterns documented in comprehensive validation studies, particularly those that have employed knockout models .

What experimental models are most appropriate for studying MAS1L function in pain modulation?

For investigating MAS1L's role in nociception:

• Cell culture models: Neuronal cell lines or primary sensory neurons can be used to study MAS1L signaling pathways. PC-12 cells have been validated for MAS1L expression .

• Animal models: Rat models have been validated for MAS1L studies , and appropriate knockout models provide crucial experimental controls .

• Tissue samples: Examine MAS1L expression in dorsal root ganglia and other pain-relevant tissues using validated antibodies .

• Functional assays: Calcium imaging, electrophysiology, and behavioral pain tests can be combined with MAS1L manipulation to study functional outcomes.

• Genetic approaches: Consider CRISPR-Cas9 gene editing or siRNA knockdown to study loss-of-function effects in relevant model systems.

How does MAS1L interact with the renin-angiotensin system, and what methods can examine this relationship?

While MAS1L's direct interaction with the renin-angiotensin system is less characterized than that of MAS1, researchers can investigate potential relationships using:

• Co-immunoprecipitation studies to detect physical interactions between MAS1L and angiotensin receptors.

• Proximity ligation assays to visualize protein-protein interactions in situ.

• Functional assays measuring angiotensin-mediated signaling in the presence or absence of MAS1L expression.

• Comparative studies with MAS1, which is known to function as an antagonist of AGTR1 and inhibits the actions of Angiotensin II .

• RNA interference or gene editing approaches to modulate MAS1L expression and observe effects on renin-angiotensin system components.

What are the key considerations when designing experiments to study MAS1L subcellular localization?

For accurate subcellular localization studies:

• Use multiple fixation methods, as these can affect epitope accessibility and detection patterns. Compare results from formaldehyde fixation with other fixatives.

• Include co-localization studies with established markers for cellular compartments (plasma membrane, endoplasmic reticulum, Golgi apparatus).

• Consider using cell fractionation followed by Western blotting to biochemically verify localization patterns observed in microscopy.

• Be aware that MAS1L is a multi-pass membrane protein , so membrane preparation protocols should be optimized accordingly.

• Use super-resolution microscopy techniques for more precise localization when standard confocal microscopy is insufficient to resolve fine details.

How can emerging proteomics approaches complement antibody-based detection of MAS1L?

Novel proteomics techniques offer complementary approaches:

• Mass spectrometry-based techniques can identify and quantify MAS1L without antibody dependence, providing orthogonal validation.

• Proximity labeling methods (BioID, APEX) can map MAS1L protein interaction networks in living cells.

• Thermal proteome profiling can assess ligand binding to MAS1L without requiring specific antibodies.

• CRISPR-based tagging with epitope tags or fluorescent proteins can enable visualization and purification of endogenous MAS1L.

• Single-cell proteomics may reveal cell-type-specific expression patterns that are difficult to discern with traditional antibody-based methods.

What methodological approaches can address the challenges in studying GPCR interactions and signaling dynamics for MAS1L?

To study MAS1L signaling dynamics:

• Employ BRET/FRET-based assays to monitor receptor interactions and conformational changes in real-time.

• Use pathway-specific biosensors to measure downstream signaling events following MAS1L activation.

• Apply phospho-specific antibodies to track activation of downstream signaling components.

• Consider using nanobodies or single-domain antibodies, which may offer advantages in detecting specific conformational states of GPCRs.

• Implement advanced microscopy techniques such as fluorescence correlation spectroscopy (FCS) or single-molecule tracking to monitor receptor dynamics in living cells.

How should researchers approach experimental design when investigating potential MAS1L roles in disease contexts beyond pain modulation?

For expanding MAS1L research into disease contexts:

• Begin with expression profiling across diseased and healthy tissues using validated antibodies and complementary mRNA detection methods.

• Design functional studies based on known GPCR signaling pathways, considering potential roles in inflammation, cell proliferation, or tissue remodeling.

• Utilize relevant disease models, including patient-derived samples, cell lines, and animal models with appropriate genetic backgrounds.

• Consider pharmacological approaches, testing responses to known GPCR modulators and potential ligands.

• Implement genetic association studies to identify potential links between MAS1L variants and disease susceptibility or progression.